托法替布治疗伏格特-小柳-原田病。 - Suppr

Suppr

超能文献

Tofacitinib in Vogt-Koyanagi-Harada disease.

作者信息

Dutta Majumder Parthopratim, Shah Amravi, Kaushik Viswanath

机构信息

Department of Uvea, Medical and Vision Research Foundations, Sankara Nethralaya, Chennai, Tamil Nadu, India.

Department of Rheumatology, Apollo Hospital, Chennai, Tamil Nadu, India.

出版信息

Indian J Ophthalmol. 2020 Sep;68(9):1938-1939. doi: 10.4103/ijo.IJO_998_20.

DOI:10.4103/ijo.IJO_998_20

PMID:32823421

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7690541/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2608/7690541/3b07205cf4c1/IJO-68-1938-g001.jpg

相似文献

Tofacitinib in Vogt-Koyanagi-Harada disease.

Indian J Ophthalmol. 2020 Sep;68(9):1938-1939. doi: 10.4103/ijo.IJO_998_20.

[Vogt Koyanagi Harada syndrome].

Arch Soc Esp Oftalmol. 2008 Jun;83(6):385-90. doi: 10.4321/s0365-66912008000600010.

[Vogt-Koyanagi-Harada disease].

Tidsskr Nor Laegeforen. 2005 Aug 25;125(16):2195-7.

Vogt-Koyanagi-Harada disease.

Surv Ophthalmol. 2017 Jan-Feb;62(1):1-25. doi: 10.1016/j.survophthal.2016.05.002. Epub 2016 May 27.

Vogt-Koyanagi-Harada disease after head trauma.

Eur J Ophthalmol. 2007 Sep-Oct;17(5):847-52. doi: 10.1177/112067210701700527.

Vogt-Koyanagi-Harada syndrome in two patients with immunoglobulin A nephropathy.

Acta Med Okayama. 2007 Oct;61(5):305-9. doi: 10.18926/AMO/32898.

Vogt-Koyanagi-Harada syndrome in a 4-year-old child.

Pediatr Neurol. 1995 Jul;13(1):50-1. doi: 10.1016/0887-8994(95)00112-s.

Vogt Koyanagi Harada syndrome in a 15-year-old girl, steroids side effects and recurrences.

Turk J Pediatr. 2021;63(3):527-532. doi: 10.24953/turkjped.2021.03.023.

Evaluation of pulse corticosteroid therapy for vogt-koyanagi-harada disease assessed by optical coherence tomography.

Am J Ophthalmol. 2002 Sep;134(3):454-6. doi: 10.1016/s0002-9394(02)01575-1.

Vogt-Koyanagi-Harada syndrome with intracranial meningioma: an as yet unreported association.

Can J Ophthalmol. 2005 Dec;40(6):725-8. doi: 10.1016/S0008-4182(05)80089-4.

引用本文的文献

Failure of primary immunosuppressive agents in uveitis.

Indian J Ophthalmol. 2025 Jun 1;73(6):837-842. doi: 10.4103/IJO.IJO_2964_24. Epub 2025 May 28.

JAK-STAT inhibitors in noninfectious uveitis - A review.

Indian J Ophthalmol. 2025 Jun 1;73(6):807-815. doi: 10.4103/IJO.IJO_61_25. Epub 2025 May 28.

Efficacy and safety of Janus kinase inhibitors in non-infectious inflammatory ocular diseases: a prospective cohort study from the international AIDA network registries.

Front Med (Lausanne). 2024 Aug 23;11:1439338. doi: 10.3389/fmed.2024.1439338. eCollection 2024.

Use of immunomodulators in non-infectious uveitis: lights and shadows.

Eye (Lond). 2024 Dec;38(17):3231-3242. doi: 10.1038/s41433-024-03294-9. Epub 2024 Aug 19.

Rise of biologics in noninfectious uveitis: a retrospective cohort study from Nepal.

Ann Med Surg (Lond). 2023 Apr 11;85(5):1486-1489. doi: 10.1097/MS9.0000000000000546. eCollection 2023 May.

Clinical and immunological study of Tofacitinib and Baricitinib in refractory Blau syndrome: case report and literature review.

Ther Adv Musculoskelet Dis. 2022 Apr 29;14:1759720X221093211. doi: 10.1177/1759720X221093211. eCollection 2022.

Effectiveness of Baricitinib in Refractory Seronegative Rheumatoid Arthritis and Uveitis: A Case Report.

Front Med (Lausanne). 2022 Jan 14;8:764067. doi: 10.3389/fmed.2021.764067. eCollection 2021.

Commentary: Janus kinase inhibitors and their use in autoimmune ocular inflammatory disorders.

Indian J Ophthalmol. 2020 Sep;68(9):1939-1940. doi: 10.4103/ijo.IJO_1656_20.

本文引用的文献

Tofacitinib for refractory uveitis and scleritis.

Am J Ophthalmol Case Rep. 2018 Dec 4;13:53-55. doi: 10.1016/j.ajoc.2018.12.001. eCollection 2019 Mar.

Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis.

Cochrane Database Syst Rev. 2017 Mar 10;3(3):CD012591. doi: 10.1002/14651858.CD012591.

Vogt-Koyanagi-Harada disease: review of a rare autoimmune disease targeting antigens of melanocytes.

Orphanet J Rare Dis. 2016 Mar 24;11:29. doi: 10.1186/s13023-016-0412-4.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Tofacitinib in Vogt-Koyanagi-Harada disease.

Indian J Ophthalmol. 2020 Sep;68(9):1938-1939. doi: 10.4103/ijo.IJO_998_20.

[Vogt Koyanagi Harada syndrome].

Arch Soc Esp Oftalmol. 2008 Jun;83(6):385-90. doi: 10.4321/s0365-66912008000600010.

[Vogt-Koyanagi-Harada disease].

Tidsskr Nor Laegeforen. 2005 Aug 25;125(16):2195-7.

Vogt-Koyanagi-Harada disease.

Surv Ophthalmol. 2017 Jan-Feb;62(1):1-25. doi: 10.1016/j.survophthal.2016.05.002. Epub 2016 May 27.

Vogt-Koyanagi-Harada disease after head trauma.

Eur J Ophthalmol. 2007 Sep-Oct;17(5):847-52. doi: 10.1177/112067210701700527.

Vogt-Koyanagi-Harada syndrome in two patients with immunoglobulin A nephropathy.

Acta Med Okayama. 2007 Oct;61(5):305-9. doi: 10.18926/AMO/32898.

Vogt-Koyanagi-Harada syndrome in a 4-year-old child.

Pediatr Neurol. 1995 Jul;13(1):50-1. doi: 10.1016/0887-8994(95)00112-s.

Vogt Koyanagi Harada syndrome in a 15-year-old girl, steroids side effects and recurrences.

Turk J Pediatr. 2021;63(3):527-532. doi: 10.24953/turkjped.2021.03.023.

Evaluation of pulse corticosteroid therapy for vogt-koyanagi-harada disease assessed by optical coherence tomography.

Am J Ophthalmol. 2002 Sep;134(3):454-6. doi: 10.1016/s0002-9394(02)01575-1.

Vogt-Koyanagi-Harada syndrome with intracranial meningioma: an as yet unreported association.

Can J Ophthalmol. 2005 Dec;40(6):725-8. doi: 10.1016/S0008-4182(05)80089-4.

引用本文的文献

Failure of primary immunosuppressive agents in uveitis.

Indian J Ophthalmol. 2025 Jun 1;73(6):837-842. doi: 10.4103/IJO.IJO_2964_24. Epub 2025 May 28.

JAK-STAT inhibitors in noninfectious uveitis - A review.

Indian J Ophthalmol. 2025 Jun 1;73(6):807-815. doi: 10.4103/IJO.IJO_61_25. Epub 2025 May 28.

Efficacy and safety of Janus kinase inhibitors in non-infectious inflammatory ocular diseases: a prospective cohort study from the international AIDA network registries.

Front Med (Lausanne). 2024 Aug 23;11:1439338. doi: 10.3389/fmed.2024.1439338. eCollection 2024.

Use of immunomodulators in non-infectious uveitis: lights and shadows.

Eye (Lond). 2024 Dec;38(17):3231-3242. doi: 10.1038/s41433-024-03294-9. Epub 2024 Aug 19.

Rise of biologics in noninfectious uveitis: a retrospective cohort study from Nepal.

Ann Med Surg (Lond). 2023 Apr 11;85(5):1486-1489. doi: 10.1097/MS9.0000000000000546. eCollection 2023 May.

Clinical and immunological study of Tofacitinib and Baricitinib in refractory Blau syndrome: case report and literature review.

Ther Adv Musculoskelet Dis. 2022 Apr 29;14:1759720X221093211. doi: 10.1177/1759720X221093211. eCollection 2022.

Effectiveness of Baricitinib in Refractory Seronegative Rheumatoid Arthritis and Uveitis: A Case Report.

Front Med (Lausanne). 2022 Jan 14;8:764067. doi: 10.3389/fmed.2021.764067. eCollection 2021.

Commentary: Janus kinase inhibitors and their use in autoimmune ocular inflammatory disorders.

Indian J Ophthalmol. 2020 Sep;68(9):1939-1940. doi: 10.4103/ijo.IJO_1656_20.

本文引用的文献

Tofacitinib for refractory uveitis and scleritis.

Am J Ophthalmol Case Rep. 2018 Dec 4;13:53-55. doi: 10.1016/j.ajoc.2018.12.001. eCollection 2019 Mar.

Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis.

Cochrane Database Syst Rev. 2017 Mar 10;3(3):CD012591. doi: 10.1002/14651858.CD012591.

Vogt-Koyanagi-Harada disease: review of a rare autoimmune disease targeting antigens of melanocytes.

Orphanet J Rare Dis. 2016 Mar 24;11:29. doi: 10.1186/s13023-016-0412-4.